Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.
Genesys has generated more than 18 exits from 38 portfolio companies and has invested more than $250M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.
Our team has worked together for two decades of successful and continuous partnership.
Long standing relationships with leading North American research institutes and universities provide us with early insights into top-tier research discoveries and world-class innovation, as well as preferential access to high potential deal flow and deep diligence expertise.
We use our local world class research corridor as a lens to identify the most promising investment opportunities and apply our company creation strategy – a formula that has repeatedly proven its effectiveness with profitable returns.
We provide the critical expertise portfolio companies need to scale from great science on the bench to viable commercial enterprises competing in the global market. From thought leaders to executives to key advisors, our network and inhouse expertise give our companies the tools they need to perform.
Our team provides the deep domain expertise and experience needed to scale emerging opportunities in the lab into successful companies that will change the lives of countless patients around the world.
Director of Finance and Operations
Ms. Williams is Director of Finance and Operations and joined Genesys Capital in 2002. Ms. Williams brings to Genesys a well-balanced range of skills. She has a proven track record of success in implementing a variety of major projects, and in working with senior stakeholders and key contacts. During her career with Genesys she has worked closely with the team to develop the operations and is responsible for finance and administration.
Ms. Williams graduated from the University of Guelph with an Honours Bachelor of Commerce and holds an MBA from Queen's University.
Co-founder, Managing Director
Mr. Lamb is co-Founder and Managing Director of Genesys Capital. With over 20 years experience in life sciences venture capital, he is one of Canada’s most experienced investors and company builders. Since co-founding Genesys Capital in 2000, Mr. Lamb has been instrumental in raising over $300 million in venture capital funds, and has been involved in deploying over $250 million across 38 investments. He currently serves on the Boards of Flosonics Medical and the Centre for Probe Development and Commercialization at McMaster University. Mr. Lamb has served on the Board of Affinium Pharmaceuticals (acquired by Debiopharm), Ionalytics Corporation (acquired by Thermo Electron Corp.), Millenium Biologix (acquired by Medtronic) and was Chairman of the Board of Fusion Pharmaceuticals Inc., Profound Medical Corp. and DELEX Therapeutics Inc. when it was sold to YM BioSciences (now Gilead). Mr. Lamb works closely with Genesys investee companies to strategically position the companies to build value for shareholders.
Prior to co-founding Genesys Capital, Mr. Lamb was an Investment Manager with MDS Capital Corp. He is a frequently invited speaker at biotechnology industry conferences. Mr. Lamb graduated from McMaster University, Faculty of Health Sciences, with a Master of Science in Molecular Neurobiology and also holds an MBA from Queen’s University.
Mr. Stiff joined Genesys Capital in 2002 and became Partner at the firm in 2007 and Managing Director in 2016. During his tenure with Genesys, he has been responsible for investments in several early-stage portfolio companies that cross a multitude of clinical disciplines and technology areas. Current board affiliations include EBT Medical, Inc., Giiant Pharma Inc., Inversago Pharma Inc. and Veralox Therapeutics, Inc. Past board affiliations include Allostera Pharma, Fairhaven Pharmaceuticals (acquired by Liminal BioSciences Inc. NASDAQ:LMNL), gIcare Pharma, Interface Biologics, Matregen, Naurex (acquired by Allergan NYSE:AGN), NeurAxon, StemPath, Therapeutic Monitoring Systems and Zelos Therapeutics. Mr. Stiff also volunteers as a board member for BioteCanada, and as an advisor to the Ontario Genomics Institute (OGI), the Centre for Commercialization of Regenerative Medicine (CCRM) and Medicine by Design and as an associate with the Creative Destruction Lab (CDL).
Prior to joining Genesys, Mr. Stiff worked at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in the genetic diagnostics field. This experience, combined with an academic background in biology, has provided significant technical knowledge of many areas of life sciences. Mr. Stiff completed a Bachelor of Science (Honours) from Queen’s University and an MBA from the Rotman School of Management.
Co-founder, Managing Director
Mr. Holman is co-Founder and Managing Director of Genesys Capital and has extensive commercial and technical experience in the biotechnology industry. Since co-founding Genesys Capital in 2000, Mr. Holman has been actively involved in raising over $300 million of venture capital and has been instrumental in deploying over $250 million across 38 investments. He currently serves on the Board of Directors of Adapsyn Bioscience Inc., Functional Neuromodulation Ltd., IDbyDNA Inc. (observer), and Questat Inc. From 2012-2015, he was a board observer with Invitae (NYSE: NVTA). From 2001 to 2013, he served on the board of Epocal, a Genesys portfolio company acquired by Alere, now Abbott Labs (NYSE: ABT).
Prior to co-founding Genesys Capital, Mr. Holman was a Senior Investment Manager with MDS Capital Corporation. Previously, Mr. Holman worked in the laboratory of Dr. Peter St George-Hyslop at the University of Toronto where he was a key member of the international research team that discovered several genes responsible for Alzheimer’s disease. Mr. Holman holds a Bachelor of Science (Honours) in Biochemistry and an MBA, both from Queen’s University.
Chief Financial Officer
Ms. Low joined Genesys Capital in 2007 in the role of Chief Financial Officer. She has more than 20 years of experience in finance and administration in the investment fund industry. She was formerly the CFO of a retail venture capital fund manager from its inception, growth to close to $1 Billion in assets under management and on through to its wind down. Ms. Low consults to a small number investment firms and is also the head of finance for Sankoya Technologies, developer of a next-generation waste treatment solution.
Ms. Low is a Chartered Professional Accountant and holds a Master of Accounting (MAcc) from the University of Waterloo.
Dr. Ranger joined Genesys Capital as a Venture Partner in 2022 and is currently transitioning into the role of General Partner of Genesys Ventures IV LP. He has co-created and provided leadership to three of Genesys portfolio companies over the past 15 years, including gIcare pharma, Inversago Pharma Inc., and Giiant Pharma Inc. In addition to his entrepreneurial experience, he has spent several years as General Partner at AmorChem (2017-2021 ), a Montreal based early-stage life sciences venture investor.
Dr. Ranger complements the company building expertise within the Genesys partnership with his extensive operating experience and immersion in the Quebec life science ecosystem. As part of the senior investment team, he helps to anchor Genesys co-creation and start-up activity in Montreal and Quebec more broadly, one of North America’s leading innovation ecosystems. Dr.Ranger also volunteers as reviewer for Canada Foundation of Innovation (CFI), as co-chair of SME financing committee of Quebec Government’s Ministère de l’Économie et de l’Innovation (MEI) and co-chair & cofounder of the Sweet Pharma Day networking event.
Dr. Ranger holds a PhD in Chemistry and Material Sciences from Université Laval, completed a postdoctoral training at Stanford University and holds an executive MBA from ESG UQAM and Université Paris-Dauphine. Over the course of his career, he has authored 30 peer reviewed journal articles and 8 patents.
Dr. Farr joined Genesys Capital in 2020 as an Associate, bringing to the team eight years of experience at the bench in laboratory research and discovery. She is responsible for sourcing deal flow and carrying out diligence on biotech and medtech investment opportunities. She is also a board observer for Giiant Pharma Inc., EBT Medical, Inc., and Questat Inc. Before Genesys, Dr. Farr worked as a Business Development Officer in the Industry Partnerships & Commercialization office at the Hospital for Sick Children, where she managed IP, industry partnerships, and start-up opportunities.
Dr. Farr received her PhD from the Faculty of Medicine at the University of Toronto where she studied the effects of an anti-diabetic hormone on lipid and lipoprotein metabolism. She also has a Bachelor of Health Science (Honours) with a minor in Biochemistry from McMaster University.
Ms. Valerova joined Genesys Capital in 2021 as an Office Manager. She brings over 8 years of experience in Office Management, Marketing, and Project Administration. She assists in the development and implementation of firm policies and procedures, manages and oversees administrative and IT practices, and assists with communications and reporting.
Prior to joining Genesys, Ms. Valerova worked at Thornton Tomasetti and RJC Engineers in marketing, project administration and office management.
Mr. Sharma joined Genesys Capital in 2020 as an Associate, focusing on exploring cutting edge life sciences technologies and supporting current portfolio companies. He currently serves as a Board Observer at Veralox Therapeutics, Inc.
Before Genesys, Mr. Sharma worked at adMare Bioinnovations, where he was responsible for proactive identification of new opportunities, deal sourcing and financial valuations. Prior to his time at adMare, he served as a Management Consultant providing primary strategic insights to big pharma.
He has also held various scientific roles in an early drug discovery group at Eisai Inc. and in a clinical biomarker group at Alexion Pharma. He spent his early career in academic research at Abramson Cancer Center at University of Pennsylvania.
Mr. Sharma holds a Bachelor of Technology from Amity University Gurgaon, a Master of Biotechnology from the University of Pennsylvania, and an MBA from the UBC Sauder School of Business at University of British Columbia.
Jun 24, 2022 - NEW YORK – Illumina has acquired IDbyDNA, a company developing metagenomic technology for infectious disease testing and pathogen surveillance, GenomeWeb has learned today.
Jun 13, 2022 - Development program for VLX-1005, a novel small molecule 12-LOX inhibitor, awarded Fast Track designation by US Food and Drug Administration
MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer (CFO), effective immediately.
HAMILTON, Ontario & BOSTON, March 17, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the fourth quarter ended December 31, 2021 and provided an update on clinical and corporate developments.
MONTREAL (CANADA) – March 15, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, announced today the dosing of the first participant with metabolic syndrome in a Phase 1b clinical trial.
TORONTO, March 03, 2022 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2021.
FREDERICK, Md., Feb. 23, 2022 /PRNewswire/ -- Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Lisa Beck as Chief Business Officer.
Montreal, Canada – 17 January 2022 – Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the successful completion of the Phase 1 Clinical Trial for its INV-202 molecule that focuses on treating metabolic disorder complications...